TNNI3 and COVID-19: Increase of MYO—an early release biomarker of cardiac injury—showed the highest overall performance (AUC, 0.83 [95% CI, 0.80–0.86]) to predict the risk of COVID-19 mortality, followed by (NT-pro)BNP (AUC, 0.81 [95% CI, 0.78–0.85]), hs-cTnI (AUC, 0.78 [95% CI, 0.73–0.84]), and CK-MB (AUC, 0.71 [95% CI, 0.67–0.75]).